EGPA diagnosis and treatment consume significant healthcare resources, both in public and private settings. Eosinophilic granulomatosis with polyangiitis (EGPA)—a form of antineutrophil cytoplasmic ...

There have been reports of patients who have been started on peritoneal dialysis who developed CIDP shortly after. There is much that we are still learning about chronic inflammatory demyelinating ...

An initial negative peripheral blood screen for KIT D816V does not necessarily rule out a diagnosis of systemic mastocytosis. Three hundred eighty-one patients with anaphylaxis or suspected of having ...

One of the defining healthcare challenges of our age is the fair allocation of medical resources in the context of an ever-expanding population and runaway drug prices. The healthcare systems adopted ...

The new delivery system could effectively edit the huntingtin (HTT) gene in neurons derived from induced pluripotent stem cells obtained from patients with Huntington disease. A team of researchers ...

Multidisciplinary perisurgical care can best ensure the success of most surgeries for those with hemophilia. An 11-year-old boy presented with pain in his right thigh secondary to a fall 3 days prior.

BTKi monotherapy significantly prolonged time to next treatment or death compared with BCL-2i+CD20 monoclonal antibody in the second-line setting for CLL/SLL. Patients with chronic lymphocytic ...

Nipocalimab binds FcRn with high specificity, reducing IgG levels while sparing innate and adaptive immune functions. Nipocalimab effectively reduced maternal alloantibodies implicated in fetal and ...

An entrance to the CHEST 2024 conference in Boston, Massachusetts (Photo by Larry Luxner) The number of treatments for PAH continues to rise, but it still takes an an average of 3 years from symptom ...

The lifetime risk of thrombosis in patients with PNH is approximately 50%, and it tends to be found in the abdominal or cerebral veins. Patients who experience thromboses at unusual sites should be ...

Over 240 patients with ATTR-CM treated with tafamidis died over a median follow-up period of 43.2 months. More than a third (39%) of patients with transthyretin-mediated amyloid cardiomyopathy ...

Targeted disease-specific therapy should be considered in symptomatic patients with a confirmed diagnosis of post-orthotopic liver transplantation ATTR-CM. Many patients with hereditary ...